Nelson SP, Chen EH, Syniar GM, et al.; Pediatric Practice Research Group. Prevalence of symptoms of gastroesophageal reflux during infancy. A pediatric practice-based survey. Arch Pediatr Adolesc Med. 1997;151(6):569-572.
Campanozzi A, Boccia G, Pensabene L, et al. Prevalence and natural history of gastroesophageal reflux: pediatric prospective survey. Pediatrics. 2009;123(3):779-783.
Rosen R, Vandenplas Y, Singendonk M, et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr. 2018;66(3):516-554.
Quitadamo P, Urbonas V, Papadopoulou A, et al. Do pediatricians apply the 2009 NASPGHAN-ESPGHAN guidelines for the diagnosis and management of gastroesophageal reflux after being trained?. J Pediatr Gastroenterol Nutr. 2014;59(3):356-359.
Barr RG, Rajabali F, Aragon M, et al. Education about crying in normal infants is associated with a reduction in pediatric emergency room visits for crying complaints. J Dev Behav Pediatr. 2015;36(4):252-257.
Musiienko A. Commission bias. In: Raz M, Pouryahya P, eds. Decision Making in Emergency Medicine. Biases, Errors and Solutions. Springer Singapore; 2021: 77–82.
Simeone D, Caria MC, Miele E, et al. Treatment of childhood peptic esophagitis: a double-blind placebo-controlled trial of nizatidine. J Pediatr Gastroenterol Nutr. 1997;25(1):61-55.
Orenstein SR, Hassall E, Furmaga-Jablonska W, et al. Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. J Pediatr. 2009;154(4):514-520.e4.
van der Pol RJ, Smits MJ, van Wijk MP, et al. Efficacy of proton-pump inhibitors in children with gastroesophageal reflux disease: a systematic review. Pediatrics. 2011;127(5):925-935.
Higginbotham TW. Effectiveness and safety of proton pump inhibitors in infantile gastroesophageal reflux disease. Ann Pharmacother. 2010;44(3):572-576.
Boruta M, Boruta R, Li J. Acid suppression therapy and symptom improvement (or lack thereof) in children. Pediatrics. 2019;144(1):e20190909.
Quinonez RA, Garber MD, Schroeder AR, et al. Choosing wisely in pediatric hospital medicine: five opportunities for improved healthcare value. J Hosp Med. 2013;8(9):479-485.
Santana RNS, Santos VS, Ribeiro-Júnior RF, et al. Use of ranitidine is associated with infections in newborns hospitalized in a neonatal intensive care unit: a cohort study. BMC Infect Dis. 2017;17(1):375.
Terrin G, Passariello A, De Curtis M, et al. Ranitidine is associated with infections, necrotizing enterocolitis, and fatal outcome in newborns. Pediatrics. 2012;129(1):e40-e45.
Chung EY, Yardley J. Are there risks associated with empiric acid suppression treatment of infants and children suspected of having gastroesophageal reflux disease?. Hosp Pediatr. 2013;3(1):16-23.
Guillet R, Stoll BJ, Cotten CM, et al.; National Institute of Child Health and Human Development Neonatal Research Network. Association of H2-blocker therapy and higher incidence of necrotizing enterocolitis in very low birth weight infants. Pediatrics. 2006;117(2):e137-e142.
Beck-Sague CM, Azimi P, Fonseca SN, et al. Bloodstream infections in neonatal intensive care unit patients: results of a multicenter study. Pediatr Infect Dis J. 1994;13(12):1110-1116.
Rojas MA, Efird MM, Lozano JM, et al. Risk factors for nosocomial infections in selected neonatal intensive care units in Colombia, South America. J Perinatol. 2005;25(8):537-541.
Graham PL, Begg MD, Larson E, et al. Risk factors for late onset gram-negative sepsis in low birth weight infants hospitalized in the neonatal intensive care unit. Pediatr Infect Dis J. 2006;25(2):113-117.
Bianconi S, Gudavalli M, Sutija VG, et al. Ranitidine and late-onset sepsis in the neonatal intensive care unit. J Perinat Med. 2007;35(2):147-150.
Canani RB, Cirillo P, Roggero P, et al.; Working Group on Intestinal Infections of the Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics. 2006;117(5):e817-e820.
Jackson MA, Goodrich JK, Maxan M-E, et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut. 2016;65(5):749-756.
Mitre E, Susi A, Kropp LE, et al. Association between use of acid-suppressive medications and antibiotics during infancy and allergic diseases in early childhood. JAMA Pediatr. 2018;172(6):e180315.
Wang Y-H, Wintzell V, Ludvigsson JF, et al. Association between proton pump inhibitor use and risk of asthma in children. JAMA Pediatr. 2021;175(4):394-403.
Stark CM, Susi A, Emerick J, et al. Antibiotic and acid-suppression medications during early childhood are associated with obesity. Gut. 2019;68(1):62-69.
Malchodi L, Wagner K, Susi A, et al. Early acid suppression therapy exposure and fracture in young children. Pediatrics. 2019;144(1):e20182625.
Kothari S, Nelson SP, Wu EQ, et al. Healthcare costs of GERD and acid-related conditions in pediatric patients, with comparison between histamine-2 receptor antagonists and proton pump inhibitors. Curr Med Res Opin. 2009;25(11):2703-2709.
Ho T, Dukhovny D, Zupancic JAF, et al. Choosing Wisely in newborn medicine: five opportunities to increase value. Pediatrics. 2015;136(2):e482-e489.
Karagas MR, Punshon T, Sayarath V, et al. Association of rice and rice-product consumption with arsenic exposure early in life. JAMA Pediatr. 2016;170(6):609-616.
Kwok TC, Ojha S, Dorling J. Feed thickener for infants up to six months of age with gastro-oesophageal reflux. Cochrane Database Syst Rev. 2017(12):CD003211.
Beal J, Silverman B, Bellant J, et al. Late onset necrotizing enterocolitis in infants following use of a xanthan gum-containing thickening agent. J Pediatr. 2012;161(2):354-356.